title: Clinical outcome of gemcitabine/S-1 combination therapy for advanced pancreatic cancer.
authors: Junichi
authors: J
authors: Yamauchi
authors: Masashi
authors: M
authors: Kanai
authors: Shigemi
authors: S
authors: Matsumoto
authors: Takafumi
authors: T
authors: Nishimura
authors: Shujiro
authors: S
authors: Yazumi
authors: Kazuhiro
authors: K
authors: Kami
authors: Yoshiya
authors: Y
authors: Kawaguchi
authors: Hiroyasu
authors: H
authors: Yasuda
authors: Toshiyuki
authors: T
authors: Kitano
authors: Akiko
authors: A
authors: Misawa
authors: Hiroshi
authors: H
authors: Ishiguro
authors: Kiyotsugu
authors: K
authors: Yoshikawa
authors: Kazuhiro
authors: K
authors: Yanagihara
authors: Masanori
authors: M
authors: Fukushima
authors: Ryuichiro
authors: R
authors: Doi
authors: Tsutomu
authors: T
authors: Chiba
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D004361:Drug Tolerance; D006801:Humans; D010094:Oxonic Acid / Q000008:administration & dosage / Q000009:adverse effects; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000556:secondary; D012189:Retrospective Studies; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; D003841:Deoxycytidine; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D000093542:Gemcitabine